BioWorld

March 25, 2002

View Archived Issues

Gilead Files NDA For Hepatitis B Product, Seeks Priority Review

Gilead Sciences Inc. on Thursday filed a new drug application with the FDA for a hepatitis B drug expected to capture a sizeable portion of the market. (BioWorld Today) Read More

NeuroSearch, Grupo Ferrer Drop GABA Anxiety Drug In Phase I

Read More

Princeton Team Blows E. coli’s Cover, Reveals Germ’s Biofilm Formation, Predicts Antibiotics

Read More

House Committee Pursues ImClone, Wants Family Contacts

Read More

Other News To Note

Read More

Aphton Sells 1.2M Shares, Raises $12.6M For Trials, Operations

Read More

Quarterly Earnings Reports

Read More